Using primary care prescribing databases for pharmacovigilance.

AIMS In the UK, adverse drug reactions (ADRs) are responsible for over 6.5% of all hospital admissions, representing a significant morbidity and cost burden to the health service. We aimed to develop an ADR monitoring system capable of identifying the reasons for patient discontinuation of drug therapy within 6 months of the index prescription. METHODS Patients first prescribed amlodipine between 1 March 2004 and 28 February 2007 who discontinued their amlodipine medication within 6 months of the index prescription were identified from the practice team information (PTI) database. Once identified, reasons for amlodipine discontinuation were assessed by an electronic database search using relevant Readcodes and key words and by a direct approach to the primary care medical records. RESULTS The PTI database identified 995 patients [61.4% females, mean age 65.9 years (SD 12.4 years)] who discontinued amlodipine within 6 months of an index prescription. An electronic search of the database, using Readcodes, identified that 19.4% (193) of patients who discontinued their medication had an ADR recorded in the database. Six (20%) of 30 participating primary care practices, contributing to the PTI database, agreed to be approached directly and supply the reasons for discontinuation for the 51 patients identified as having discontinued amlodipine in their practices. Completed data were returned for all 51 patients, 98% of whom discontinued amlodipine due to an ADR or adverse drug event. CONCLUSIONS The results of this study confirm that primary care prescribing databases can be easily used to identify the frequency and nature of ADRs occurring in an ADR-enriched population identified through medication discontinuation.

[1]  A. Ciampi,et al.  Determinants of discontinuation of new courses of antihypertensive medications. , 2002, Journal of clinical epidemiology.

[2]  H F Sanderson,et al.  A language of health in action: Read Codes, classifications and groupings. , 1996, Proceedings : a conference of the American Medical Informatics Association. AMIA Fall Symposium.

[3]  M D Rawlins,et al.  Spontaneous reporting of adverse drug reactions. , 1986, The Quarterly journal of medicine.

[4]  Teresa Waring,et al.  The information management and technology strategy of the UK National Health Service – Determining progress in the NHS acute hospital sector , 2000 .

[5]  I. Osterloh,et al.  The safety of amlodipine. , 1989, American heart journal.

[6]  David W. Wainwright,et al.  The Information Management and Technology Strategy of the UK National Health Service: Quo Vadis? , 2013, UKAIS.

[7]  M. Pirmohamed,et al.  Adverse drug reactions: back to the future. , 2003, British journal of clinical pharmacology.

[8]  M. Brisson,et al.  Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study , 2005, Journal of Human Hypertension.

[9]  E. Strocchi,et al.  A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice , 2007, Vascular health and risk management.

[10]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[11]  J. Imbs,et al.  Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients , 2005, International journal of clinical practice.

[12]  R. Milne,et al.  Audit of populations in general practice: the creation of a national resource for the study of morbidity in Scottish general practice. , 1998, Journal of epidemiology and community health.

[13]  A. Fletcher,et al.  Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population , 1995, BMJ.

[14]  Colin Simpson,et al.  Using Routinely Collected Prescribing Data to Determine Drug Persistence for the Purpose of Pharmacovigilance , 2011, Journal of clinical pharmacology.

[15]  B. Bloom Continuation of initial antihypertensive medication after 1 year of therapy. , 1998, Clinical therapeutics.

[16]  L. Ruilope,et al.  Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. , 2005, Clinical therapeutics.

[17]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[18]  Thomas A Burke,et al.  Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice , 2006, Journal of hypertension.

[19]  L. Wilton,et al.  Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study , 1998, BMJ.

[20]  C. E. Lumley,et al.  The under-reporting of adverse drug reactions seen in general practice , 1986 .

[21]  W. Zidek,et al.  Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension , 1995 .

[22]  N. Fowler,et al.  Differentiation of constrictive pericarditis and restrictive cardiomyopathy by radionuclide ventriculography. , 1989, American heart journal.

[23]  J. Caro,et al.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  M D Rawlins,et al.  Spontaneous reporting of adverse drug reactions. I: the data. , 1988, British journal of clinical pharmacology.

[25]  R. Fogari,et al.  Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension , 2007, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[26]  G. Baio,et al.  A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. , 2002, Clinical therapeutics.